ASH Annual Meeting : Episode 1

Video

RESPONSE Trial Validates Ruxolitinib in Polycythemia Vera

Ruben A. Mesa, MD, from Mayo Clinic Cancer Center, Scottsdale, AZ, describes exciting findings from the phase III RESPONSE trial for polycythemia vera (PV).

The RESPONSE trial compared ruxolitinib and best available therapy in patients with PV who were intolerant of or resistant to first-line therapy is hydroxyurea. Researcher found that ruxolitinib was superior to best available therapy in terms of hematocrit, splenomegaly, and achieving a complete remission. Based on the RESPONSE study findings, ruxolitinib was FDA approved on December 4, 2014 as a second-line therapy for PV.

At ASH 2014, Mesa presented data related to the quality-of-life benefits from ruxolitinib. Benefits were seen at both the individual symptom level, eg, including itching, night sweats, etc.; and at the aggregate symptom level.

Additionally, Mesa discusses data related to patients who crossed-over to ruxolitinib after 32-weeks of best available therapy. Patient receiving this delayed treatment with ruxolitinib experienced high levels of response, comparable to those who had initially received ruxolitinib. These findings support the primary RESPONSE results and further validate the efficacy of ruxolitinib in this patient population.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity